IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cell Carcinoma (MCC)
Clinical trial NCT06940440 · RECRUITING
Trial details
- NCT number
- NCT06940440
- Sponsor
- TuHURA Biosciences, Inc.
- Status
- RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2025-10-01
- Primary completion
- 2026-05-31
- Enrollment
- 9
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.